Qiagen N.V. (QGEN)

Market Cap	8.80B
Revenue (ttm)	1.98B
Net Income (ttm)	83.59M
Shares Out	216.12M
EPS (ttm)	0.38
PE Ratio	106.96
Forward PE	17.68
Dividend	$1.32 (3.24%)
Ex-Dividend Date	Jan 29, 2025

Volume	1,732,261
Open	40.77
Previous Close	41.44
Day's Range	40.04 - 41.07
52-Week Range	37.63 - 47.93
Beta	0.62
Analysts	Buy
Price Target	49.79 (+22.27%)
Earnings Date	May 7, 2025

About QGEN

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN
• Website: https://www.qiagen.com

Financial Performance

In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.

Analyst Forecast

According to 9 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $49.79, which is an increase of 22.27% from the latest price.

Price Target

$49.79

(22.27% upside)

Analyst Consensus: Buy